Research progress of anti-apoptotic inhibitor venetoclax in treatment of myeloid leukemia

doi:10.16352/j.issn.1001-6325.2023.05.0833

Abstract

Abstract: The anti-apoptotic protein Bcl-2 inhibitor venetoclax (Ven) can significantly improve the remission rate and long-term survival of elderly and relapsed/refractory acute myeloid leukemia(AML) patients who are not sensitive to intensive chemotherapy. TP53/FLT3 mutation, abnormal energy metabolism of fatty acids and amino acids, high expression of Mcl-1 protein and activation of ferroptosis program occur during clinical treatment are all involved in the development of Ven resistance and leukemia progression. Further exploration of the mechanisms leading to Ven resistance in myeloid leukemia may help to inhibit the development of Ven resistance and continuously improve the long-term survival of leukemia patients.

Key words: acute myeloid leukemia, venetoclax(Ven), apoptosis, ferroptosis

CLC Number:

XIANG Caixia, HUANG Bintao, HAO Jian. Research progress of anti-apoptotic inhibitor venetoclax in treatment of myeloid leukemia[J]. Basic & Clinical Medicine, 2023, 43(5): 833-836.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/10.16352/j.issn.1001-6325.2023.05.0833

http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/Y2023/V43/I5/833

References

[1]Roldán Pérez A,Vázquez Paganini JA, Penalva Moreno MJ,et al. Real-life experience of venetoclax and hypomethylating agents in acute myeloid leukemia patients not candidates for intensive chemotherapy or who are refrac-tory/relapsed: a single-centre experience[J].Clin Case Rep,2022:6116-6130.
[2]Pei S,Pollyea DA,Gustafson A,et al.Monocyticsubclonesconferresistance to venetoclax-based therapy in patients with acute myeloid leukemia[J]. Cancer Discov, 2020,536-551.
[3]Richter A,Lange S,Holz C, et al. Effective tumor cell abrogation via venetoclax-mediated BCL-2 inhibitionin KMT2A-rearrange dacute B-lymphoblastic leukemia[J].Cell Death Discov,2022,1:302-313.
[4]Janotka Ł, Messingerová L,Šimoničová K,et al. Changes in apoptotic pathwaysin MOLM-13 cell lines after induction of resistance to hypomethylating agents[J].Int J Mol Sci, 2021, 19:2076-3000.
[5]Cojocari D, Smith BN, Purkal JJ,et al.pevonedistat and azacitidine upregulate NOXA (PMAIP1)toincrease sensitivity to venetoclax in preclinical models of acute myeloid leukemia[J].Haematologica, 2022,1:825-835.
[6]DiNardo CD, Pratz KW, Letai A, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study[J].Lancet Oncol, 2018: 216-228.
[7]于文静,贾晋松,王婧,等.维奈克拉联合阿扎胞苷治疗急性髓系白血病的近期疗效:单中心数据[J]. 中华血液学杂志,2022:134-140.
[8]王鹏,张露巍,陆棽琦,等.维奈克拉联合阿扎胞苷与地西他滨联合预激方案治疗老年复发急性髓系白血病的疗效及安全性比较的初步观察[J].中华内科杂志,2022,157-163.
[9]苏鹏忠,何家驩,于姗,等. Met-tRNAi~(Met)载体蛋白在急性髓系白血病(AML)中的表达及功能[J].基础医学与临床,2021:501-507.
[10]DiNardo CD,TiongI S,Quaglieri A et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML[J]Blood,2020,12,791-803.
[11]Zhang Q,Riley-Gillis B,Han L,et al.Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclaxin acute myeloid leukemia[J].Signal Transduct Target Ther,2022:51-64.
[12]Jones CL,Stevens BM,Pollyea DA,et al.Nicotinamide metabolism mediates resistance to venetoclax in relapsed acute myeloid leukemia stem cells[J].Cell Stem Cell,2020,5:748-764.
[13]Stevens BM,Jones CL,Pollyea DA,et al. Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells[J]. Nat Cancer, 2020,1: 1176-1187.
[14]Kapoor I, Bodo J, Hill BT, et al. Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance[J].Cell Death Dis, 2020,2: 941-952.
[15]Sarif Z, Tolksdorf B, Fechner H,et al. Mcl-1 targeting strategies unlock the proapoptotic potential of TRAIL in melanoma cells[J]. Mol Carcinog, 2020:1256-1268.
[16]Zhao WH, Huang BT, Zhang JY, et al. Distinct EphB4-mediated mechanisms of apoptotic and resistance to dasatinib in human chronic myeloid leukemia and K562 cell lines[J]. Leuk Res, 2017:28-33.
[17]Shi X, Zhu M, Gong Z,et al.Homoharringtonine suppresses LoVo cell growth by inhibiting EphB4 and the PI3K/AKT and MAPK/EKR1/2 signaling pathways[J].Food Chem Toxicol,2020:110960.doi: 10.1016/j.fct.2019.110960.
[18]Dixon SJ, Lemberg KM, Lamprecht MR, et al.Ferroptosis: an iron-dependent form of nonapoptotic cell death[J].Cell, 2012:1060-1072.
[19]Yang WS, SriRamaratnam R, Welsch ME, et al.Regula-tion of ferroptotic cancer cell death by GPX4[J]. Cell, 2014 Jan 16;317-331.
[20]Bersuker K, Hendricks JM, Li Z, Magtanonget al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis[J].Nature,2019:688-692.
[21]Kraft VAN, Bezjian CT, Pfeiffer S,et al. GTP Cyclohy-drolase 1/tetrahydrobiopterin counteract ferroptosis through lipid remodeling[J].ACS Cent Sci, 2020,22:41-53.
[22]Li W, Luo LX, Zhou QQ,et al. Phospholipid peroxidation inhibits autophagy via stimulating the delipidation of oxidized LC3-PE[J]. Redox Biol,2022, 5,102421. doi: 10.1016/j.redox.2022.102421.
[23]Pollak N,Lindner A,Imig D,et al.Cell cycle progression and transmitotic apoptosis resistance promote escape from extrinsic apoptosis[J].Cell Sci, 2021,15: 1-15.
[24]Lin L, Ding D, Xiao X, et al.Ametinib potentiates TRAIL-induced apoptosis via FBW7-dependent Mcl-1 degradation in colorectal cancer cells[J]. Cell Mol Med,2020,24: 6822-6832.
[25]Yoon JY, Woo SM, Seo SU, et al. Autophagy inhibitor, enhances the apoptotic effects of TRAIL through miR-216a-5p-mediated DR5 upregulation and DUB3-mediated Mcl-1 downregulation[J].Int J Mol Sci, 2021,21:17-30.